This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.
Unlike the usual late-onset Alzheimer's disease (LOAD), early-onset AD (EOAD), with onset before age 65, includes a high percentage of phenotypic variants. These non-familial, variants (vEOAD) present, not with progressive memory loss, but with language, visuospatial, or other cognitive difficulties. AD is now understood as a disorder that manifests with disturbed cognition reflecting disturbed neural networks. A multivariate analysis of neuropsychological tests, the "gold standard" for objectively defining neurocognitive impairments, coupled with structural and functional neuroimaging analysis of connectomes, can identify the neurocognitive-neural network profiles of vEOAD patients, compared to those with typical AD. This knowledge can increase our understanding of the heterogeneity of AD and how it causes disease. This study hopes to show that vEOAD constitutes a "Type 2 AD", by (1) defining the neuropsychological components of Type 2 AD, and (2) understanding the anatomy and atrophy of the brains of vEOAD patients. Together, these components can outline the neurocognitive-neural network profile of Type 2 AD. In addition to information that can help in the diagnosis and management of EOAD, this study can stimulate novel research into the reasons for this neurobiological heterogeneity in AD and could potentially lead to interventions based on alternate neurocognitive-neural network profiles.
Study Type
OBSERVATIONAL
Enrollment
180
UCLA Department of Neurology
Los Angeles, California, United States
Alzheimer's disease Subtype
Neuropsychological testing results for use in a two-stage multivariate diagnostic method that combines the (weighted) test results in order to best discriminate Type 2 AD and typical AD.
Time frame: Performed at baseline
Change in overall Neurological profile
Change in performance on neurological tasks between baseline visit and follow-up visit.
Time frame: Performed at baseline and 1-year follow-up visit
Brain atrophy in MRI - Magnetic Resonance Imaging of the brain
Images from initial MRI scan taken at baseline visit will be analyzed for atrophy and white matter tract integrity
Time frame: Performed at baseline visit
Change in overall Neuropsychological profile
Change in neuropsychological performance over time.
Time frame: Performed at baseline and 1-year follow-up visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.